Ceregene (San Diego, CA) a clinical-stage biopharmaceutical company focused adeno-associated virus vector-based gene therapy for Parkinson’s and Alzheimer’s disease, closed a $11.5M Series D financing. Participants include Hamilton BioVentures, Alta Partners, MPM Capital and Investor Growth Capital.